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An 18-yr-old, primigravid, primiparous woman
was transferred to New England Medical Center
Hospital (NEMCH) for management of postpartum
renal insufficiency.
The patient was in good health until she devel-
()ped proteinuria and mild hypertension at the end
of her sixth month of pregnancy. She was admitted
to a local hospital and treated with bedrest. At that
time, the blood urea nitrogen (BUN) concentration
was 10 mg1100 ml, the serum creatinine concentra-
tion was 0.8 mgIlOO ml, the creatinine clearance
was 144 cc/mm, the serum uric acid concentration
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was 7.5 mg/l00 ml, and the blood pressure was in
the range of 140/100 mm Hg at bedrest.
Three weeks later, the patient's diastolic blood
pressure increased to 110 mm Hg, and hydralazine
was administered in an i.v. dosage of approximately
1 mg/l0-min interval, for 8 to 10 hr. The blood pres-
sure did not respond adequately, and a cesarean
section was performed under general anesthesia be-
cause of the severe hypertension. The patient was
not hypotensive during the procedure; the fetus
died shortly after delivery. Following extubation,
the patient suddenly became cyanotic, hypotensive,
and comatose, and she was reintubated with diffi-
culty. B ronchoscopy revealed greenish material
thought to be aspirated gastric contents. A chest ra-
diograph was consistent with a right pneumothorax.
Steroids and a cephalosporin antibiotic were admin-
istered, and a chest tube was placed. The patient
improved, and approximately 24 hr after insertion
the endotracheal and chest tubes were removed.
Shortly thereafter, oozing of blood was noted at the
surgical sites. Plasma fibrinogen, which was pre-
viously 455 mg, declined to 175 mg/lOO ml. The
platelet count fell from 125,000 to 55,000/mm3.
Heparin was administered in an i.v. dose of 10,000
U, and she was transferred to NEMCH.
On admission, the patient was in marked respira-
tory distress. Physical examination revealed the fol-
lowing findings: blood pressure, 180/120 mm Hg;
respiratory rate, 36/mm; pulse, 110/mm; temper-
ature, 36° C; head, eyes, ears, nose, and throat
were unremarkable; the right side of the chest was
hyperresonant with decreased breath sounds and
diffuse rhonchi; the abdomen was mildly distended;
the surgical wounds and vagina were oozing bright
red blood; the extremities had multiple ecchy-
moses; and there was no peripheral edema. Neuro-
logic examination was grossly normal. Cardiac ex-
amination revealed an S4 gallop and a Grade TI/VT
systolic ejection murmur. Laboratory findings dis-
closed the following: serum sodium, 129 mEq;
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serum potassium, 4.3 mEq; serum chloride, 95
mEq; serum bicarbonate, 18 mEq/liter; BUN, 34
mg; serum creatinine, 3.7 mg; total serum protein,
4.8 g; serum albumin, 2.8 g; serum calcium, 7.2 mg;
serum phosphorous, 5.5 mg; serum uric acid, 19.6
mg; serum bilirubin, 3.1 mg/100 ml; serum alkaline
phosphatase, 3 Bodansky U; serum lactate dehy-
drogenase, 720 U; serum glutamic oxatoacetic
transaminase, 39 U; serum glutamic pyruvic trans-
aminase, 33 U; hemoglobin, 7.5 gIlOO ml; hemato-
crit, 23.1%; white blood cell count, 17,200/mm3;
platelet count, 14,000/mm3; prothrombin time, 23
sec (control, 12 sec); reptilase time, 50 sec (control,
15 sec); partial thromboplastin time> 2 mm; throm-
bin time > 1 mm; euglobulin lysis time > 2 hr; fi-
brinogen, 132 mg/l00 ml; fibrin split products, 2,560
gI100 ml (control, 10 g/100 ml); and a peripheral
blood smear revealed multiple schistocytes and hel-
met cells. Results of urinalysis revealed: specific
gravity, 1.009; pH, 6; proteinuria (2+); red blood
cells> 100/high power field (HPF); and white blood
cells, 2 to 4/HPF with no casts. While receiving
100% oxygen by face mask, arterial blood findings
were: pH, 7.28; arterial oxygen tension, 70 mm Hg;
and arterial carbon dioxide tension, 34 mm Hg,
Multiple blood and urine cultures were sterile. An
i.v. urogram showed kidneys of normal size with no
evidence of obstruction. An emergency chest radio-
graph disclosed a right pneumothorax and a left
lower-lobe infiltrate.
Endotracheal and chest tubes were again in-
serted, and the patient's blood pressure was con-
trolled with sodium nitroprusside. A Swan-Ganz
catheter was inserted to monitor left ventricular fill-
ing pressure. Heparin therapy was continued for ap-
proximately 24 hr, and the coagulation parameters
gradually returned to normal. The urine output
slowly increased, and the serum creatinine reached
a maximum concentration of 5.1 mg/100 ml on the
fourth hospital day. The patient's respiratory func-
tion improved, and she was extubated on the fifth
day. Four weeks after admission, the serum creati-
nine concentration was 2.4 mg/l00 ml, and the he-
matocrit was 29%; the patient was discharged. Two
weeks later, the serum creatinine concentration was
1.6 mg/l00 ml, and the patient felt well. Results of
urinalysis revealed proteinuria (2+) and 3 to 5 red
blood cells/HPF. One year later, the serum creati-
nine concentration was 0.9 mg/l00 ml.
Discussion
DR. T. F. FERRIS: This primiparous woman rep-
resents a classic example of fulminant toxemia with
hypertension, proteinuria, azotemia, and con sump-
tive coagulopathy. She developed hypertension and
proteinuria without microscopic hematuria or cy-
linduria in approximately the 28th week of gesta-
tion. To manifest these initial signs of toxemia so
early in pregnancy is somewhat unusual and gener-
ally presages severe disease. At that time, the
serum creatinine concentration was 0.8 mg, and the
blood urea nitrogen (BUN) concentration was 10
mg, but the serum urate concentration was 7.5 mgI
100 ml.
Recognition of the different norms for renal func-
tion and blood pressure during pregnancy is of pri-
mary importance in caring for the pregnant patient.
Since there is an increase in renal blood flow and
glomerular filtration rate (GFR) in pregnancy, the
normal values for BUN (8.7 1.5 mg/100 ml) and
serum creatinine (0.46
.06 mg/l00 ml) are signifi-
cantly lower in pregnant women, Thus, a BUN con-
centration of 15 mg or a serum creatinine concentra-
tion of 1.2 mg/lOO ml, for example, indicates an ap-
proximate 50% reduction in GFR in a pregnant
patient. Similarly, blood pressure, particularly dias-
tolic pressure, normally decreases during preg-
nancy. Mean arterial pressure (diastolic + 1/3 pulse
pressure) is 72 9 mm Hg in the 22nd week of
pregnancy and increases to only 82 8 mm Hg by
the 40th week; thus, a mean arterial pressure of 93
mm Hg (120/80) is abnormally high in pregnancy. In
pregnant women with toxemia, the blood pressure
is usually higher, but early recognition of the dis-
ease depends on an appreciation of the normal re-
duction in blood pressure that occurs during preg-
nancy.
For some time, the reduction in diastolic blood
pressure in normal pregnancy was thought to result
from an arteriovenous fistula in the uteroplacental
circulation. The decrease in blood pressure, how-
ever, occurs in the first trimester, before there is a
great increase in uterine blood flow and despite an
approximate 50% increase in cardiac output. There-
fore, peripheral vasodilatation probably plays a
prominent role. Reduced peripheral resistance in
pregnant women is frequently evidenced in the skin
by the development of spider telangiectases, and
thenar and hypothenar erythema. In addition to ar-
teriolar dilation, smooth muscle relaxation is seen
in other systems during pregnancy. The genito-
urinary tract develops the so-called physiological
hydronephrosis; the stomach and gall bladder evi-
dence decreased peristalsis, and there is decreased
pulmonary airway resistance with increase in vital
capacity.
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Among the many hormonal changes seen in preg-
nancy, there is a striking increase in plasma renin
activity (PRA), which is attributable only in part to
increased renin substrate concentration [1]. Preg-
nant women ingesting unrestricted diets have su-
pine PRA values of approximately 14 ng/ml/hr com-
pared with approximately 2 ng/mllhr in nonpregnant
women; upright PRA values in pregnant women are
25 to 30 nglml/hr. It has been postulated that this
increase in renin secretion results from the con-
comitant increase in progesterone secretion that oc-
curs in pregnancy. Progesterone, an aldosterone an-
tagonist, might induce salt wasting, but pregnant
women retain approximately 900 mEq of sodium
during the course of gestation and have normal abil-
ity to maintain sodium balance with a sodium intake
as low as 10 mEq/day (Bay WH, Ferris TF: Factors
controlling plasma renin and aldosterone during
pregnancy, submitted for publication). Salt restric-
tion in pregnancy causes PRA and plasma aldos-
terone level to increase appropriately, but during
a sodium intake of 300/mEq/day PRA and plasma
aldosterone fail to suppress normally. After 6 days
of a 300 mEq/day sodium intake, pregnant women
have supine PRA of 6.0 1.2 ng/mllhr, compared
with 0.2 0.1 ng/ml/hr in nonpregnent women (Fig.
I). This failure of PRA to be suppressed is not due
to posture since even at bedrest pregnant women
who are given i.v. saline (3 liters/day, for 2 days)
persist in having elevated PRA.
One attractive possibility to account for the hy-
perreninemia of pregnancy is suggested by recent
evidence linking the secretion of renin with that of
prostaglandin. The intrarenal infusion of prosta-
glandin E2 (PGE2) or its substrate, arachidonic acid,
increases renin secretion. Although this effect could
be due to peripheral antagonism at receptor sites,
PGE has been demonstrated to stimulate renin se-
cretion directly in renal cortical cell cultures [2].
The uteroplacental vascular bed in pregnant rabbits
is an extraordinary source of both renin and PGE
[3]. A PGE concentration of 172.0 48.0 nglml
has been found in uterine venous blood; this con-
trasts with a renal venous PGE concentration of
0.4 0.1 ng/ml. Expressed differently, PGE secre-
tion by the uterus in pregnant rabbits is approxi-
mately 3000 ng/min compared with 500 ng/min from
both kidneys. Following the inhibition of prosta-
glandin synthesis with meclofenamate or indometh-
acm, uterine vein PGE concentration decreases,
and uteroplacental blood flow decreases from ap-
proximately 6 to 2% of cardiac output. Whether
PGE secreted by the kidney or the uterus affects
arterial blood PGE or plays a role in the regulation
of blood pressure is unclear. When PGE2 is injected
into the right ventricle, at least 66% is oxidized to
inactive metabolites in a single passage through the
pulmonary vasculature [4]. In pregnant women,
however, higher plasma and urinary PGE concen-
trations are found than in nonpregnant women. We
have found a peripheral vein PGE concentration of
0.45 0.06 ng/ml with urinary PGE excretion of
2780 357 ng/24 hr in third trimester pregnant
Since the immunoassay cannot differentiate between PGE1 and
POE2, values are expressed as POE.
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Fig. 1. Supine plasma renin activity (PRA) in pregnant (dashed
line) and nonpregnant (solid line) women while ingesting a 300
mEqlday sodium diet,for6 days (P < .01). (The data were taken
from Bay and Ferris.)
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Fig. 2. Urinary prostaglandin E (PGE) excretion in third trimes-
ter pregnant women and in nonpregnant women (P <
.025). (The
data were taken from Bay and Ferris.)
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Fig. 3. Variations in angiotensin sensitivity throughout preg-
nancy by comparison of the mean angiotensin dose (nglml/hr)
required to evoke a pressor response. Closed circles denote
women with normotensive pregnancy. Open circles denote wom-
en who developed toxemia during pregnancy. Dashed line de-
notes nonpregnant mean. P values represent differences between
the two groups at the various weeks of gestation. (Reproduced
with permission of A,n Soc Clin Invest [7].)
women, compared with 0.10 0.01 ng/ml and
1191 142 ng/24 hr, respectively, in nonpregnant
women (P < .025) (Fig. 2).
The source of urinary PGE is thought to be renal
synthesis because renal cortical dehydrogenase rap-
idly oxidizes PGE2 when infused into the renal ar-
tery [5]. Thus, the increase in uterine PGE syn-
thesis during pregnancy may reflect a generalized
increase in prostaglandin synthesis in various vas-
cular sites. It is known that prostacyclin (PGI2), a
potent vasodilator, can be synthesized by a micro-
somal enzyme found in blood vessel walls. Thus, it
would be of great interest to know whether the ex-
cretion of 6 keto-prostaglandin F10, the metabolite
PGI2, is also increased in pregnancy. Recent studies
suggest that PGI2 rather than PGE2 causes increase
in renin synthesis by renal cortical cells [2].
On the basis of these findings, pregnancy can be
regarded as analogous to Bartter's syndrome in
which hypersecretion of renin and aldosterone is as-
sociated with increased urinary PGE concentration,
with renin and aldosterone secretion returning to-
ward normal following treatment with indomethacin
[6]. In spite of increased aldosterone secretion, po-
tassium wasting, a feature of Bartter's syndrome, is
not present in pregnancy; this may be due to in-
creased progesterone secretion during pregnancy or
to other factors that prevent the usual kaliuretic re-
sponse to aldosterone.
The increased PGE synthesis may explain the re-
sistance to angiotensin that occurs in pregnancy and
may have relevance to the mechanism of hyper-
tension during toxemia. Plasma renin and angioten-
sin II concentrations are known to be lower in tox-
emia than in normotensive pregnancy [1], but this
effect may be more than offset by the exquisite sen-
sitivity to angiotensin that develops in toxemia.
Studies by Gant et al [7], utilizing serial angiotensin
infusions in primigravid women, have demonstrated
resistance to the pressor effects of angiotensin as
early as the 10th week of normal pregnancy. In
women destined to develop toxemia, however, sen-
sitivity begins to increase by the 18th to 20th week
(Fig. 3). With the development of overt toxemia,
sensitivity to angiotensin exceeds that in non-
pregnant women. In contrast, women who do not
develop toxemia maintain insensitivity to angioten-
sin throughout pregnancy. Everett, Worley, and
MacDonald have recently reported that indometha-
cm reverses the insensitivity to angioten sin in preg-
nant women, suggesting that it is caused by prosta-
glandin synthesis [8]. It is tempting to speculate
from these observations that the increase in angio-
tensin sensitivity and hypertension characteristic of
toxemia is due to a decrease in prostaglandin syn-
thesis. If true, hypertension would be the result not
of excess of a vasoconstrictor, but deficiency of a
vasodilator.
Obstetricians have generally felt that treating hy-
pertension in the pregnant patient with toxemia re-
duces uteroplacental blood flow. There is no evi-
dence for this in toxemia, and experimental studies
in pregnant rabbits have demonstrated that the uter-
oplacental circulation autoregulates flow over a
wide range of perfusion pressure. With mean arteri-
al perfusion pressure ranging from 140 to 60 mm
Hg, no change in uteroplacental blood flow is de-
tected [9]. To postulate that reducing blood pres-
sure in toxemia reduces uteroplacental blood flow
implies that flow is a linear function of pressure in
the uterine bed. I feel administration of hydralazine
or diazoxide to reduce blood pressure in the preg-
nant patient with toxemia is a reasonable therapeu-
tic maneuver that does not compromise uterine
blood flow and may prevent intracerebral hemor-
rhage and congestive heart failure.
Regardless of the mechanisms responsible for the
hypertension in toxemia, elevated blood pressure
does not provide an adequate explanation for the
renal changes characteristic of this condition. The
renal pathology in toxemia consists of bloodless
glomeruli with occlusion of the capillary lumen by
P.05 Pi P.01 P.001 1
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endothelial cell swelling described as "glomerular
endotheliosis." Electron microscopic studies reveal
fibrin-like material in the subendothelial area, and
immunofluorescent studies show fibrin deposits in
glomeruli [10]. This lesion is thought to represent a
low-grade consumptive coagulopathy or Shwartz-
man reaction occuring in toxemia. The Shwartzman
reaction can be induced experimentally in pregnant
rabbits by administration of one challenging dose of
endotoxin, whereas two challenges are needed in
the nonpregnant animal. The first dose of endotoxin
triggers the clotting cascade causing platelet aggre-
gation, activation of thromboplastin, and generation
of fibrinogen and fibrin. The reticuloendothelial sys-
tem is thought to prevent the characteristic fibrin
deposits in the kidney after the first dose by phago-
cytising fibrin and other products of the clotting sys-
tem. However, the second dose of endotoxin, ad-
ministered 24 hr later, reactivates the clotting sys-
tem and overwhelms the reticuloendothelial system
with resultant fibrin thrombi in the kidneys, lungs,
liver, and spleen. The coagulation system of the
pregnant animal is thought to be under constant
challenge by slow release of trophoblastic material
from the uterus and placenta[ll]. If true, any addi-
tional stimulus for coagulation in pregnancy could
more readily evoke the Shwartzman reaction.
Moreover, during pregnancy there is an increase in
the concentration of several coagulation factors:
primarily Factor I (fibrinogen), Factor VII, Factor
VIII, and Factor X. These changes, which tele-
ologically are thought to protect against hemor-
rhage during pregnancy, could also play a role in the
high incidence of intravascular clotting. Plasmino-
gen concentration is higher, and plasminogen acti-
vator is lower in pregnancy; the latter tends to de-
crease fibrinolytic activity. Serial studies during
pregnancy demonstrate a trend toward a decreased
platelet count with increased fibrin degradation
products in serum as early as the 18th week in wom-
en destined to develop toxemia (Fig. 4) [12]. It is
intriguing that the changes in fibrin degradation
products and platelet count occur at about the same
time that angiotensin sensitivity increases in the
pregnant patient who develops toxemia. Urinary fi-
brin degradation products are increased significant-
ly 24 hr postpartum in patients with toxemia (Fig.
5). Interestingly, consumptive coagulopathy ap-
peared in the patient under discussion approximate-
ly 24 hr postpartum.
Although I believe the consumptive coagulopathy
in the present patient was related to toxemia, some
mention should be made of amniotic fluid embolism
as an alternative explanation. Amniotic fluid embo-
lism is frequently manifested clinically by dissemi-
nated intravascular coagulation, but the setting in
this patient was not typical. Amniotic fluid embo-
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Fig. 4. Serial study of serum fibrin degradation products (FDP)
in 10 patients who developed severe preeclampsia compared
with levels in 20 healthy control patients. Open circles denote the
JO patients who developed preeclampsia; closed circles denote
the 20 healthy control patients; and the solid horizontal line de-
notes nonpregnant women (mean SEM). (Reproduced with per-
mission of John Wiley & Sons, Inc. [12].
/
24 hr postpartum 144 hr postpartum
Fig. 5. Urinary fibrin degradation products (FDP) following de-
livery in normal pregnancy and in pregnancy corn plicated by
preeclampsia. Shaded boxes denote patients with preeclampsia;
and unshaded boxes denote patients with normal pregnancy
(mean sEM). The P values at 24 and 144 hr are < 0.05 and <
0.005, respectively. (Reproduced with permission of John Wiley
& Sons, Inc. [12].
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lism is more apt to occur in multiparous women fol-
lowing a prolonged and difficult labor. The patient
under discussion, on the other hand, had a perfectly
uncomplicated cesarean section. The pulmonary
problem in this woman was complicated by aspira-
tion, and the slow resolution of the pneumonia was
probably a reflection of the necrotizing nature of as-
piration pneumonitis. Following amniotic fluid em-
bolism, the chest radiograph can be similar to that
following aspiration, but the findings of gastric con-
tents in the bronchial secretions confirm the pres-
ence of aspiration. The pneumothorax brings up the
possibility of mediastinal emphysema, which can
occur during labor because of an increase in airway
pressure, but in this patient it was probably the re-
suit of forced breathing during anesthesia.
Cortical necrosis is more often the cause of acute
renal failure in the pregnant patient, than in the non-
pregnant patient, because of the frequent associa-
tion of consumptive coagulopathy and obstetrical
catastrophes. In a study of 38 patients with cortical
necrosis, the origin of the problem in 26 patients
was obstetrical, and consumptive coagulopathy was
present in most of the patients studied [13]. There
was concern in this patient that irreversible thrombi
had developed in the renal vasculature. The renal
failure was of short duration, however, and the
creatinine clearance of greater than 100 cc/mm in
the followup period rules out cortical necrosis. Al-
though slow improvement in renal function can oc-
cur following cortical necrosis, one would not ex-
pect return to a normal creatinine clearance. The
cause of the acute renal failure in this patient was
probably fibrin deposits in the renal vasculature.
Whether full-blown cortical necrosis occurs in the
setting of fibrin deposition may simply depend on
the magnitude of the intrarenal clotting.
As a brief aside, let's consider the significance of
the patient's initial serum urate concentration of 7.5
mg/l00 ml. I believe this value is quite compatible
with toxemia. Normal serum urate concentration in
pregnancy is approximately 3 mg/l00 ml, and an
elevated value is the most accurate laboratory in-
dicator for assessing the severity of toxemia. It is a
better early indicator of renal involvement in tox-
emia than BUN concentration or creatinine clear-
ance. As demonstrated in the present patient, de-
creased urate clearance can occur with normal
creatinine clearance. It has been postulated that
placental hypoxia increases arterial lactate concen-
tration, which decreases urate clearance; arterial
concentration of lactate, however, is not uniformly
elevated in toxemia. Also, there is no consistent
correlation between arterial lactate concentration
and serum urate concentration [14]. Reduction in
renal blood flow with maintenance of GFR during
infusion of norepinephrine and angiotensin de-
creases urate clearance, presumably by decreasing
urate delivery to tubular secretory sites [15]. A sim-
ilar hemodynamic change may explain the de-
creased urate clearance in toxemia, as well as that
following volume depletion and diuretic administra-
tion. The serum urate concentration of 19.6 mg/lOO
ml in this patient following delivery is excessive for
uncomplicated toxemia, but is consistent with acute
renal failure particularly in the presence of in-
creased urate production. Hemolysis from con-
sumptive coagulopathy, widespread tissue injury
from microthrombi, and the underlying toxemia
probably accounted for the patient's severe hyper-
uricemia.
Although the bleeding diathesis is impressive in
patients with consumptive coagulopathy, the cause
of death is usually intravascular thrombosis. The
use of a Swan-Ganz catheter in such a patient is
questionable because it could serve as a nidus for
thrombus formation. In spite of the catheter, the pa-
tient developed acute pulmonary edema, presum-
ably because volume expansion and hypertension
were aggravated by administration of blood prod-
ucts. Whether to administer fibrinogen and clotting
factors in a patient with consumptive coagulopathy
is an unsettled question. In this patient, the fibrin-
ogen concentration was 132.0 mgIlOO ml, and the
administration of fibrinogen might only add fuel to
the fire. The condition is usually self-limited, and
with treatment of the underlying cause, in this case
delivery of the fetus, the process abates. Moreover,
the use of heparin in a patient with toxemia is haz-
ardous. Death in patients with toxemia is usually
the result of intracerebral hemorrhage; thus, hepa-
rin administration in a hypertensive pregnant wom-
an would seem contraindicated. Some have recom-
mended the use of heparin postpartum, but al-
though platelet survival may improve there is no
clinical evidence to suggest that patient survival is
improved. The same is probably true of consump-
tive coagulopathy generally, regardless of its cause.
It is tempting to try to tie together the hyper-
tension and consumptive coagulopathy in toxemia.
If one postulates that the increased angiotensin sen-
sitivity, and hence the hypertension of toxemia, is
due to a decrease in the synthesis of a prostaglandin
with dilating properties, one might further speculate
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that the intravascular coagulation is also due to an
aberration in prostaglandin synthesis. Such an hy-
pothesis is possible. Arachidonic acid is converted
by the cyclo-oxygenase enzyme to the endoperox-
ide, prostaglandin G2 (PUG2), which can then be
synthesized into either thromboxane A2 (TA2),
PGI2, or PGE2. Since PGI2, which is synthesized by
blood vessel walls, is both an antagonist to platelet
aggregation and a vasodilator, it may oppose the ef-
fect of TA2, a platelet aggregator and vasoconstric-
tor synthesized in platelets (Fig. 6). A balance be-
tween synthesis of PGI2 in blood vessel walls and
TA2 in platelets may be necessary in normal preg-
nancy to prevent clotting [16]. An aberration in this
control system in toxemia, on the other hand, could
be responsible for intravascular clotting. Obvious-
ly, more knowledge is needed in this area to under-
stand the changes that occur in toxemia as well as in
other states associated with intravascular coagu-
lation.
Questions and Answers
DR. J. T. HARRINGTON: In view of the evident
deterioration in this patient's renal function—serum
creatinine concentration increased from 3.7 to 5.0
mg/lOO mi—and the evidence of desseminated intra-
vascular coagulation, would you have recommend-
ed heparin therapy in this particular patient?
DR. T. F. FERRIS: I think the judgment con-
cerning the use of heparin in this situation is based
on one's prejudice. The literature does not indicate
that survival in any series of patients with consump-
tive coagulopathy has improved with heparin. Since
toxemia is complicated by hypertension, imminent
delivery, and, most hazardous of all, intracerebral
hemorrhage, it seems to me that administration of
heparin is contraindicated. The coagulopathy is
usually self-limited and in this particular patient was
relatively mild with only minimal depression of the
fibrinogen.
DR. J. P. KASSIRER: Two questions, Dr. Ferris.
First, what do you think is the etiology of the pa-
tient's renal failure, and, second, is there in your
opinion any validity to the concept that a distur-
bance in the coagulation system is responsible for
acute tubular necrosis?
DR. T. F. FERRIS: I think the cause of her renal
failure was acute tubular necrosis. Acute renal fail-
ure with cortical necrosis may occur in patients
with desseminated intravascular coagulation, but
fortunately acute renal failure with recovery is more
common. I think that the acute renal failure in this
Fig, 6. A model of possible role of prostaglandin synthesis in
blood clotting. Model illustrates proslacyclin (P012) synthesis in
blood vessel walls, left, and thromboxane (TA2) synthesis in
platelets, right. In coagulation system, P012, an antagonist to
platelet aggregation and vasodilator, opposes TA2, a platelet ag-
gregator and vasoconstrictor. Balance between synthesis of PGI2
and TA2 may be necessary to prevent clotting in normal preg-
nancy. (Reproduced with permission of Geron-X, Inc., Publish-
ers [16].)
patient was similar to that following gram-negative
sepsis, which may involve mechanisms similar to
the Shwartzman reaction.
DR. J. J. COHEN: You speculated that decreased
synthesis of PGE might play an important patho-
genic role in toxemia. Have levels of PGE been
measured in pregnant patients with toxemia to see if
they are low?
DR. T. F. FERRIS: A study needs to be done simi-
lar to Gant's angiotensin sensitivity study with pro-
spective urinary PGE throughout pregnancy to see
if a decrease occurs at about the 24th week of gesta-
tion in women who develop toxemia.
DR. J. J. COHEN: it is clear that PGE synthesis
can be inhibited by several agents, but are there any
substances that are known to increase PGE syn-
thesis?
DR. T. F. FERRIS: No therapeutic agent is known,
but we have found that lithium and potassium defi-
ciency increases urinary PGE in the dog.
DR. F. J. GENNARI (NEMCH): Would it not be
possible to explore whether a decrease in prosta-
glandin synthesis is playing a role in toxemia by in-
Platelet
Platelet
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hibiting PGE synthesis in pregnant rabbits and
seeing if blood pressure increases?
DR. T. F. FERRIs: If an anesthetized pregnant
rabbit is given indomethacin, the blood pressure
does increase. Yet, Saralasin (P—113, 1—sar—8—ala—
angiotensin II) causes the blood pressure to decrease
indicating the importance of angiotension in main-
taining blood pressure in the pregnant animal. I sus-
pect that prostaglandin synthesis, particularly PGE2
and PGI2, account for the vasodilation and increase
in renin secretion with pregnancy. How TA2 fits
in the overall picture is unclear.
DR. J. J. COHEN: Is there any evidence to suggest
that antiprostaglandin agents precipitate pre-
eclampsia clinically?
DR. T. F. FERRIS: Turner and Collins [17] have
reported that perinatal mortality is higher in preg-
nant women taking aspirin. The study does not look
specifically at the incidence of toxemia, but on the
basis of animal studies I wouldn't recommend pros-
taglandin inhibiting drugs during pregnancy.
RENAL FELLOW: In view of the increased sensi-
tivity to angiotensin in pregnant women with tox-
emia, what is your feeling about treating hyper-
tension in pregnancy with diuretics that might sec-
ondarily increase renin and angiotension levels?
DR. T. F. FERRIS: In toxemia, there is a de-
creased plasma volume, so hematocrit values in
pregnant patients with toxemia tend to be higher
than in normotensive pregnant women. This does
not mean that the patient is volume depleted, but
rather this is the same type of phenomenon that oc-
curs with a pheochromocytoma and renal artery
stenosis, where venous constriction decreases
venous capacitance with a shift of fluid into the in-
terstitial space. Following relief of the vasoconstric-
tion, plasma volume is reconstituted as extra-
cellular fluid returns from the interstitial space. The
initial therapy in toxemia with hemoconcentration
should not be a diuretic, but rather a vasodilator:
hydralazine, nitroprusside, or diazoxide. In the
edematous patient with toxemia who is not hemo-
concentrated, I believe a diuretic can be safely ad-
ministered. The risk of diuretics in toxemia is over-
emphasized by many obstetricians. Twenty years
ago, diuretics were given almost routinely to preg-
nant women to prevent edema. There was no evi-
dence that diuretics did harm, although they did not
prevent toxemia. When Gant et al [18, 19] devel-
oped the dehydroepiandrosterone (DHEA) clear-
ance technique as a measure of uterine blood
flow, he reported that diuretics or antihypertensive
agents reduced the DHEA clearance, and the use of
diuretics became unpopular. There is evidence,
however, that the DHEA clearance is not an accu-
rate method for measurement of uterine blood flow
since the normal DHEA clearance is only 25 ml!
mm, whereas uterine blood flow is approximately
500 mllmin at term [20].
DR. N. E. MADIAS (NEMCH): Would you please
comment on the results of a recent study by Hauth,
Cunningham, and Whalley [21] in which some 350
nuiliparous women with pregnancy-induced hyper-
tension prior to term were managed conservatively
and were not given antihypertensive agents. About
90% of the women were delivered at or beyond the
37th week of gestation; there were no maternal
deaths, and an impressively low perinatal mortality
rate was observed. Do you think that clinical mon-
itoring of such patients in a high-risk pregnancy unit
is a reasonable therapy?
DR. T. F. FERRIS: If 100 patients with malignant
hypertension are treated with bedrest, not all will
die immediately. I don't believe that argues against
treating them with antihypertensive drugs. Thus,
the argument for not treating hypertension in tox-
emia has never appealed to me. Toxemia has a dis-
tinct mortality, and although there are no figures to
prove that antihypertensive therapy prevents intra-
cerebral hemorrhage in toxemia the experience with
these drugs in other hypertensive diseases suggests
they would. When pregnant women with toxemia
spend several days or weeks without treatment
awaiting fetal growth and development, I am fearful
of the mother's health. Early delivery is obviously
one way of treating the hypertension.
DR. C. CETRULO (St. Margaret's Hospital for
Women): I believe the originators of this series
wished to demonstrate that there is a role for con-
servative management in patients with hyper-
tension. This view encourages conservative man-
agement in an attempt to bring patients with hyper-
tension to a point where the fetus will survive, and
it is felt that conservative management can some-
times prove to be beneficial even in preeclampsia.
DR. T. F. FERRIS: My concern is that these pa-
tients with preeclampsia have hypertension and
may have fibrin thrombi in the cerebral vessels.
Convulsions and central nervous system hyper-
excitability cannot always be correlated with the
height of the blood pressure alone.
RENAL FELLOW: What is your view on the use of
magnesium sulfate in the pregnant patient with hy-
pertension?
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DR. T. F. FERRIS: Magnesium sulfate has a dual
role: It is an anticonvulsant and a vasodilator. It
was once used in the treatment of malignant hyper-
tension, but it proved to be relatively ineffective. It
is a reasonable anticonvulsant; Valium (diazepam)
and Dilantin (phenytoin) are better. As a vasodila-
tor, hydralazine and diazoxide are far more potent.
Magnesium sulfate is popular in obstetrics because
obstetricians have a great deal of experience in its
use.
RENAL FELLOW: Do you have any comments on
how the postulated abnormality in the balance be-
tween angiotensin and prostaglandin correlates with
the tendency for preeclampsia to occur in young
women and in women from lower socioeconomic
groups?
DR. T. F. FERRIs: There is no question that the
primiparous woman is at greater risk. I think this
could be a reflection of lack of development of the
uterine circulation in a primiparous woman. PGE
may be involved in new blood vessel growth in the
uterus and placenta; as you know, a patent ductus
arteriosus can be closed with indomethacin. Per-
haps in the young primiparous woman, uterine PGE
synthesis capacity is not fully developed. The so-
cioeconomic factors may be related to the poor hav-
ing children at an earlier age and to the lack of pre-
natal care. Prenatal care would allow detection of
an increase in blood pressure and proteinuria at an
early stage.
DR. N. E. MADIAS: The overwhelming majority
of women with toxemia seem lo recover with little
difficulty after delivery. When severe eclampsia oc-
curs, however, there is approximately a 20% in-
cidence of acute renal failure [22]. Is there some
way to identify the patient who is destined to devel-
op acute renal failure in this setting?
DR. T. F. FERRIS: Fortunately, the incidence of
acute renal failure in patients with typical, less se-
vere, preeclampsia is much lower than 20%. In any
event, I don't know how to predict which women
will develop renal failure except that in general it is
more apt to occur when consumptive coagulopathy
occurs.
DR. J. T. HARRINGTON: Patients have been de-
scribed with postpartum renal failure, who appar-
ently have not had preeclampsia. What do you con-
sider to be the cause of the renal failure in this group
of patients?
DR. T. F. FERRIS: These patients would seem to
have a postpartum Schwartzman reaction; some
have had preceding toxemia, others have not. The
cause of the intrarenal clotting is not known.
Reprint requests to Dr. T. F. Ferris, Department of Medicine,
University of Minnesota, 420 De/eware Street S.E., Minneapo-
us, Minnesota 55455, U.S.A.
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